What’s the PD-L1 expression guidance on sintilimab vs. pembrolizumab with/without chemotherapy in untreated patients
PD-L1 Expression Guidance: Sintilimab vs. Pembrolizumab PD-L1 Expression Guidance: Sintilimab vs. Pembrolizumab When it comes to treating untreated patients with PD-L1 expression, the choice between sintilimab and pembrolizumab can be crucial. Both drugs are immune checkpoint inhibitors that target the…
